← All organizations
Highest phase reached
Phase 3
First clinical trial
Jan 1, 2009First marketed drug
Jul 20, 2012First NDA
Jul 20, 2012Last known activity
Mar 31, 2017
Acquired by Amgen on Jan 1, 2013
Timeline
1990s
- Jan 1, 1992
Onyx— Founded
2000s
- Jan 1, 2009
Proteolix— Acquired
2010s
- Jul 20, 2012
carfilzomib— NDA Organization
- Jan 1, 2013
Amgen— Acquired By
Drugs by trial phase (17 distinct, 26 trials)
Phase 3 (4 own, 0 via acquisition)
Phase 2 (8 own, 0 via acquisition)
Phase 1 (5 own, 0 via acquisition)
Indications
Approved for
Studied for
Marketed drugs (1)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (26)
- NCT03029234CollaboratorPhase 3Mar 31, 2017
- NCT02899052CollaboratorPhase 2Jan 19, 2017
- NCT02937571CollaboratorPhase 1/Phase 2Oct 1, 2016
- NCT02294357CollaboratorPhase 2Dec 1, 2014
- NCT02042950CollaboratorPhase 2Jul 1, 2014
- NCT02095834CollaboratorPhase 1Apr 1, 2014
- NCT02405364CollaboratorPhase 2Feb 1, 2014
- NCT01775930CollaboratorPhase 2Oct 1, 2013
- NCT02360345CollaboratorPhase 1Sep 1, 2013
- NCT01969565CollaboratorPhase 2Aug 1, 2013
- NCT01813227CollaboratorPhase 2Apr 1, 2013
- NCT01729104CollaboratorPhase 1/Phase 2Apr 1, 2013
- NCT01585870CollaboratorPhase 1Jul 1, 2012
- NCT01559935CollaboratorPhase 2Mar 1, 2012
- NCT01372540CollaboratorPhase 1Feb 1, 2012
Details
- Founded
- South San Francisco, CA, US Jan 1, 1992
- First NDA
- Jul 20, 2012
- Last known activity
- Mar 31, 2017
Designations held
- Orphan drug
- Fast track
- Accelerated approval
Notes
Acquired by Amgen